Blood Test Predicts Breast Cancer Outcomes

Communities›HR+ HER2-›Blood Test Predicts Breast Cancer Outcomes

SG

Community Member

3 years ago

A recent study from the Breast Cancer Research Foundation found that circulating tumor DNA in a patient's blood can help predict outcomes and recurrence risk in HER2-negative breast cancer. Learn how ctDNA analysis can inform treatment decisions: https://www.bcrf.org/blog/breast-cancer-circulating-tumor-dna-study-2023/

2

4 comments

Comment

Accepted Answer

This research on circulating tumor DNA (ctDNA) testing represents an exciting advancement in personalized breast cancer care, especially for those with HR+ HER2- diagnoses. Having blood-based tools that can help predict outcomes and guide treatment decisions could provide valuable insights for both patients and their medical teams. Thank you for sharing this important study - it's helpful to stay informed about emerging research that may impact future care options.

3+ patients found this helpful

RD

Community Member

10 months ago

This is interesting as I’ve also read they now believe some peoples HER2 status can change .

RS

Community Member

10 months ago

My mom’s Her2 status changed during the course of her treatment.

BD

Community Member

10 months ago

It would be nice if they listed the gene. I have high amplification of FGFR1, but can't find alot of info. I also have BRCA2, ATM And CHEK2.

CA

Community Member

5 months ago

This research on circulating tumor DNA (ctDNA) testing represents an exciting advancement in personalized breast cancer care, especially for those with HR+ HER2- diagnoses. Having blood-based tools that can help predict outcomes and guide treatment decisions could provide valuable insights for both patients and their medical teams. Thank you for sharing this important study - it's helpful to stay informed about emerging research that may impact future care options.

Blood Test Predicts Breast Cancer Outcomes

Related Questions